TSHA Taysha Gene Therapies, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1806310 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.1%
TTM net income YoY-56.1%
TTM EPS YoY-27.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,935.4%
Net margin-2,844.6%
FCF margin-2,582.6%
EBITDA margin-2,913.6%
Returns
ROE-54.2%
ROA-41.5%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.13x
Current ratio18.56x
Interest coverage-5,193.77x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue13.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $5.49M | $0 | $1.99M | $2.30M | $2.02M |
| R&D expense | $28.77M | $38.64M | $33.81M | $24.95M | $25.75M | $20.14M | $15.56M | $15.32M |
| SG&A expense | $13.11M | $12.15M | $9.68M | $8.83M | $8.28M | $8.60M | $8.16M | $6.63M |
| Operating income | -$41.87M | -$47.35M | -$43.49M | -$28.30M | -$34.02M | -$26.75M | -$21.42M | -$19.93M |
| Interest expense | $4,000 | $6,000 | $9,000 | $12,000 | $15,000 | $17,000 | $19,000 | $22,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.13M | -$46.64M | -$42.41M | -$27.85M | -$32.73M | -$26.88M | -$21.53M | -$18.79M |
| EBITDA | -$41.67M | -$46.95M | -$43.19M | -$28.00M | -$33.82M | -$26.45M | -$21.14M | -$19.63M |
| EPS (basic) | -0.10 | -0.13 | -0.12 | — | -0.09 | -0.09 | -0.08 | — |
| EPS (diluted) | -0.10 | -0.13 | -0.12 | — | -0.09 | -0.09 | -0.08 | — |
| Weighted avg. shares (diluted) | 406.11M | 369.04M | 366.63M | — | 353.31M | 297.99M | 269.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $422.83M | $455.41M | $276.58M | $319.77M | $297.34M | $312.76M | $116.59M | $139.04M |
| Current assets | $426.06M | $461.43M | $282.25M | $324.65M | $299.95M | $316.26M | $120.71M | $142.13M |
| PP&E, net | $2.53M | $2.41M | $6.45M | $6.74M | $6.80M | $6.96M | $7.24M | $7.49M |
| Total assets | $435.03M | $470.43M | $300.35M | $343.32M | $316.55M | $333.33M | $138.36M | $160.36M |
| Current liabilities | $22.95M | $25.98M | $20.10M | $26.55M | $28.63M | $25.35M | $22.56M | $26.23M |
| Long-term debt | $47.33M | $49.26M | $48.96M | $50.11M | $50.85M | $41.05M | $42.45M | $43.94M |
| Total debt | $47.33M | $49.26M | $48.96M | $50.11M | $50.85M | $41.05M | $42.45M | $43.94M |
| Total liabilities | $78.06M | $83.17M | $88.41M | $96.38M | $97.56M | $84.60M | $83.30M | $88.84M |
| Shareholders' equity | $356.97M | $387.27M | $211.94M | $246.94M | $218.99M | $248.73M | $55.06M | $71.53M |
| Net debt | -$375.50M | -$406.15M | -$227.62M | -$269.66M | -$246.49M | -$271.71M | -$74.14M | -$95.09M |
| Shares outstanding | 325.88M | 325.30M | 287.28M | 285.05M | 273.92M | 272.73M | 205.05M | 204.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.91M | -$40.42M | -$40.88M | -$26.72M | -$24.17M | -$20.18M | -$22.02M | -$18.31M |
| Capital expenditure | $443,000 | -$1,000 | $24,000 | $250,000 | $108,000 | $2,000 | $378,000 | -$2,000 |
| Free cash flow | -$33.36M | -$40.42M | -$40.90M | -$26.97M | -$24.27M | -$20.18M | -$22.40M | -$18.31M |
| Investing cash flow | -$443,000 | $1,000 | -$3.02M | -$247,000 | -$48,000 | $62,000 | -$371,000 | $13,000 |
| Financing cash flow | $785,000 | $216.66M | $711,000 | $49.56M | $8.80M | $216.29M | -$52,000 | -$357,000 |
| Depreciation & amortization | $200,000 | $400,000 | $295,000 | $299,000 | $200,000 | $300,000 | $283,000 | $304,000 |
| Stock-based compensation | $6.08M | $5.81M | $5.55M | $3.53M | $3.29M | $3.19M | $3.29M | $3.22M |
Free plan shows the latest 8 periods; Pro shows all 28 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.